Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Becton Dickinson and Co (BDX) Com Stk USD 1

Sell:$226.61 Buy:$226.62 Change: $6.55 (2.81%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Change: $6.55 (2.81%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Change: $6.55 (2.81%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Contact details

1 Becton Dr
United States
+1 (201) 8476800

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$63.26 billion
Shares in issue:
271.17 million
Health Care Equipment
New York Stock Exchange
United States
US dollar

Key personnel

  • Vincent Forlenza
    Executive Chairman of the Board
  • Thomas Polen
    President, Chief Executive Officer, Chief Operating Officer, Director
  • Christopher Reidy
    Chief Financial Officer, Executive Vice President, Chief Administrative Officer
  • Betty Larson
    Executive Vice President- Human Resources, Chief Human Resources
  • Samrat Khichi
    Executive Vice President, General Counsel
  • James Borzi
    Executive Vice President - Global Operations, Chief Supply Chain Officer
  • Simon Campion
    Executive Vice President and President, BD Interventional Segment
  • Roland Goette
    Executive Vice President, President - EMEA
  • Patrick Kaltenbach
    Executive Vice President, President - Life Sciences
  • Ching leong
    Executive Vice President and President, Greater Asia

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.